SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

China Accepts Innovent's Sintilimab Combination for Review

China's NMPA accepted Innovent's sintilimab combination for review in melanoma.

Related stories